Physician profile
Christopher Firely
NPI 1104354737
$3,853.31
in general payments reported to CMS, 2019-2025
23 companies · $43.72 in 2025
The $43.72 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.65 · 2021: $609 · 2022: $1,184 · 2023: $1,017 · 2024: $975 · 2025: $43.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $586.70 | 2022-2024 | |
| Amgen INC. | $546.53 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $384.14 | 2021-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $364.18 | 2021-2022 | |
| Daiichi Sankyo INC. | $260.78 | 2022-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $253.08 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $240.46 | 2022-2024 | Onpattro |
| Abbott Laboratories | $208.97 | 2021 | |
| Novo Nordisk INC | $161.35 | 2022-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.34 | 2022-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.26 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $93.59 | 2022-2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $88.09 | 2022-2024 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $87.59 | 2024 | Eliquis |
| Kiniksa Pharmaceuticals, Ltd. | $84.99 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $54.47 | 2022 | |
| Edwards Lifesciences Corporation | $48.82 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $46.02 | 2021-2023 | Nexletol |
| Allergan, INC. | $23.65 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $23.42 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $19.36 | 2024 | Savvywire |
| Chiesi USA, INC. | $13.02 | 2023 | Kengreal, Cleviprex |
| Bayer Healthcare Pharmaceuticals INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Firely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.